background ahn influenza virus high tandem potent consent vaccine need product rapidly mf adj reduce antigen require per dose allow spare rapid vaccine avail method two multicent phase ii trial conduct value safety immunogen mfadjuv cell culturederiv anc among adult year old elderly subject particle equal random receive bulldogs Î¼g hemagglutinin halides vaccine week apart outcome base center biology value research review ber committee medicine product human use camp license criterion tier seroconvers day solicit reaction adverse event ass wwwclinicaltrialsgov not result met age group hemagglutin formal reaction frequency tend higher group mild model intent vaccinerel serious occur concur well tower unit state european 